Luke Thomas Power sold $1.7M of CAI
See Remarks at Caris Life Sciences, Inc.. 62,250 shares at an average of $26.58, traded Dec 11, 2025, filed Dec 12, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.7M at market
- +10Share of holdings soldSold 38% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +6.5%, 3m -32.2%, 6m -32.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002072013-25-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 11, 2025 | MOption exercise Common Stock10b5-1 | +24,750 | $2.44 | $60k | 124,321 | Dec 12, 2025 |
| Dec 11, 2025 | MOption exercise Common Stock10b5-1 | +37,500 | $2.44 | $92k | 161,821 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stock10b5-1 | -60,850 | $26.56 | $1.6M | 100,971 | Dec 12, 2025 |
| Dec 11, 2025 | SOpen-market sale Common Stock10b5-1 | -1,400 | $27.16 | $38k | 99,571 | Dec 12, 2025 |
| Dec 11, 2025 | MOption exercise Stock Optionderivative10b5-1 | -24,750 | $0.00 | $0 | 0 | Dec 12, 2025 |
| Dec 11, 2025 | MOption exercise Stock Optionderivative10b5-1 | -37,500 | $0.00 | $0 | 0 | Dec 12, 2025 |
Related signals
Other insiders at Caris Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $239k 7,500 shares | -4% | |
| 60Notable | Caris Life Sciences, Inc. | Brian J Brille See Remarks | $12M 400,000 shares | -63% | |
| 48Moderate | Caris Life Sciences, Inc. | David Baxley Spetzler President | $15M 597,212 shares | -39% | |
| 69Notable | Caris Life Sciences, Inc. | Jon Halbert director | $990k 68,000 shares | +11% | |
| 69Notable | Caris Life Sciences, Inc. | Jeff L Vacirca director | $501k 31,050 shares | +167% | |
| 61Notable | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $101k 4,184 shares | +84% | |
| 41Moderate | Caris Life Sciences, Inc. | David Baxley Spetzler President | $9,540 400 shares | +0% | |
| 59Moderate | Caris Life Sciences, Inc. | Brian J Brille See Remarks | $630k 30,000 shares | +23% | |
| 47Moderate | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $158k 7,500 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.